This trial is looking at a new radiotracer, Ga-68 PSMA-HBED-CC, to see if it can detect metastatic prostate cancer early. Investigators will use a test and re-test design to see how well the radiotracer works.
1 Primary · 1 Secondary · Reporting Duration: 60 minutes post-injection
1 Treatment Group
1 of 1
30 Total Participants · 1 Treatment Group
Primary Treatment: (68Ga)PSMA-HBED-CC · No Placebo Group · Phase < 1
Who is running the clinical trial?
Age 18+ · Male Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- Afshar-Oromieh, Ali, Eleni Avtzi, Frederik L. Giesel, Tim Holland-Letz, Heinz G. Linhart, Matthias Eder, Michael Eisenhut, et al.. 2014. “The Diagnostic Value of PET/CT Imaging with the 68ga-labelled PSMA Ligand HBED-CC in the Diagnosis of Recurrent Prostate Cancer”. European Journal of Nuclear Medicine and Molecular Imaging. Springer Science and Business Media LLC. doi:10.1007/s00259-014-2949-6.
- Jilg, Cordula A., Vanessa Drendel, H. Christian Rischke, Teresa Beck, Werner Vach, Kathrin Schaal, Ulrich Wetterauer, Wolfgang Schultze-Seemann, and Philipp T. Meyer. 2017. “Diagnostic Accuracy of Ga-68-hbed-cc-psma-ligand-pet/ct Before Salvage Lymph Node Dissection for Recurrent Prostate Cancer”. Theranostics. Ivyspring International Publisher. doi:10.7150/thno.18421.
- Janet Pollard 2016. "Biodistribution/Reproducibility Ga-68 PSMA-HBED-CC". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02952469.
Frequently Asked Questions
How many participants are being considered for inclusion in this clinical research?
"Sign-ups for this particular research project have been closed. First published on July 14th 2016 and last edited on January 29th 2021, other trials may be more suitable if you are seeking to participate in a clinical study. Currently, 1252 studies related to prostate cancer and 17 (68Ga)PSMA-HBED-CC trials are actively recruiting patients." - Anonymous Online Contributor
Are there any opportunities for patients to participate in this clinical investigation currently?
"Unfortunatley, the recruitment period for this clinical trial has concluded. It first went up on July 14th 2016 and was last edited on January 29th 2021. If you are looking to join another study there are currently 1252 trials seeking participants with prostate cancer and 17 studies that require (68Ga)PSMA-HBED-CC patients." - Anonymous Online Contributor
What medical issues does (68Ga)PSMA-HBED-CC typically address?
"(68Ga)PSMA-HBED-CC has been approved for treating prostate cancer and is also effective in managing skin disorders such as eczema, dyshidrotic, psoriasis, and neurodermatitis." - Anonymous Online Contributor